Lineage Cell Therapeutics (LCTX) Total Debt Growth (3y) (2017 - 2021)
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Total Debt Growth (3y) (2017 - 2021) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.08% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.52% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.76% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.30% |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 63.35% |
| Dec 31, 2020 | 45.44% |
| Sep 30, 2020 | 45.44% |
| Jun 30, 2020 | -41.78% |
| Mar 31, 2019 | -61.48% |
| Dec 31, 2018 | -41.01% |
| Sep 30, 2018 | -48.85% |
| Jun 30, 2018 | -20.74% |
| Mar 31, 2018 | 90.69% |
| Dec 31, 2017 | 76.34% |
| Sep 30, 2017 | 55.79% |
| Jun 30, 2017 | 258.53% |